AIを活用した臨床試験ソリューションプロバイダーの世界市場規模調査、臨床試験フェーズ別(フェーズI、フェーズII、フェーズIII)、アプリケーション別(腫瘍、心血管系疾患、神経系疾患・症状、感染症、その他)、エンドユーザー別(製薬会社、アカデミア、その他)、地域予測 2022-2028Global AI-based Clinical Trials Solution Provider Market Size study, By Clinical Trial Phase (Phase-I, Phase-II, Phase-III), By Application (Oncology, Cardiovascular Diseases, Neurological Diseases or Conditions, Infectious Diseases, Others), By End-use (Pharmaceutical Companies, Academia, Others), and Regional Forecasts 2022-2028 世界のAIベースの臨床試験ソリューションプロバイダー市場は、2021年に約XX百万米ドルと評価され、予測期間2022-2028年にはXX%以上の健全な成長率で成長すると予測されています。臨床試験における研究開発活動に... もっと見る
サマリー世界のAIベースの臨床試験ソリューションプロバイダー市場は、2021年に約XX百万米ドルと評価され、予測期間2022-2028年にはXX%以上の健全な成長率で成長すると予測されています。臨床試験における研究開発活動に人工知能(AI)が登場することで、業務能力の向上、コストの最小化、創薬の促進が支援されます。ビッグデータと統合されたAI技術は、臨床試験の様々な主要課題の解決に役立ち、市場の成長を牽引しています。臨床試験数の増加、多くの段階における試験の効率性と生産性を高めるためのAIベースのプラットフォームの浸透の拡大などの要因が、製薬会社やCRO部門の発展と相まって、世界市場の成長を促しています。例えば、Statistaのレポートによると、2018年、世界で登録された臨床研究の総数は293,259件と記録され、この数字は絶えず上昇し、2022年には409,300件に達するとされています。したがって、臨床研究の増加は、全世界のAIベースの臨床試験ソリューションプロバイダー市場の成長にプラスの影響を及ぼしています。しかし、臨床現場におけるAIの精度の低さや、AIを用いた臨床試験の承認に関するいくつかの厳しい規制の賦課が、2022年から2028年の予測期間における市場の成長を妨げています。また、さまざまな治療領域における研究開発投資の増加、臨床試験分野における人工知能(AI)の認知度の向上と多様なアプリケーションは、予測期間中に市場需要の触媒として作用すると予想されます。世界のAIベースの臨床試験ソリューションプロバイダー市場の調査において考慮された主要地域は、アジア太平洋、北米、ヨーロッパ、ラテンアメリカ、およびその他の地域です。北米は、有利な政府政策の利用可能性と、多くのAIベースのスタートアップ企業の存在の高まりにより、市場シェアの面で世界の主要地域となっています。一方、アジア太平洋地域は、予測期間2022年から2028年にかけて最も高いCAGRを示すと予測されています。AIベースのツールの採用拡大、患者数の増加、さまざまな疾患の有病率の増加などの要因が、アジア太平洋地域のAIベースの臨床試験ソリューションプロバイダー市場に有利な成長見通しをもたらすと考えられます。 本レポートに含まれる主な市場プレイヤーは以下の通りです: Unlearn.AI, Inc. サーマ・テクノロジーズ アンティドート・テクノロジーズ(Antidote Technologies, Inc. イノプレクサス Mendel.ai メディエント・テクノロジーズ シンフォニーAI バイオエイジ・ラボズ社 アイキュア、エルエルシー ヘイローヘルスシステムズ 本調査の目的は、近年の様々なセグメント&国の市場規模を定義し、今後8年間の値を予測することです。本レポートは、調査対象地域や国ごとに、業界の質的・量的な側面を取り入れるよう設計されています。さらに、市場の将来的な成長を規定する推進要因や課題など、重要な側面に関する詳細な情報も提供しています。さらに、本レポートでは、主要企業の競争環境と製品提供の詳細な分析とともに、関係者が投資するためのミクロ市場での利用可能な機会も組み込んでいます。市場の詳細なセグメントとサブセグメントを以下に説明します: 臨床試験フェーズ別 フェーズI フェーズII フェーズ-III アプリケーション別 オンコロジー 循環器系疾患 神経系疾患 感染症 その他 エンドユーザー別 製薬会社 アカデミア その他 地域別 北アメリカ 米国 カナダ 欧州 英国 ドイツ フランス スペイン イタリア ROE アジア・パシフィック 中国 インド 日本 オーストラリア 韓国 ロアパック ラテンアメリカ ブラジル メキシコ その他の地域 さらに、本調査で考慮した年は以下の通りです: 過去年 - 2018年、2019年、2020年 基準年 - 2021年 予測期間 - 2022年~2028年 市場調査における世界のAIを活用した臨床試験ソリューションプロバイダー市場のターゲットオーディエンス: 主要コンサルティング会社・アドバイザー 大企業、中堅企業、中小企業 ベンチャーキャピタル 付加価値再販業者(VAR) サードパーティナレッジプロバイダー 投資銀行家 投資家 目次Chapter 1. Executive Summary1.1. Market Snapshot 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Million) 1.2.1. AI-based Clinical Trials Solution Provider Market, by Region, 2020-2028 (USD Million) 1.2.2. AI-based Clinical Trials Solution Provider Market, by Clinical Trial Phase, 2020-2028 (USD Million) 1.2.3. AI-based Clinical Trials Solution Provider Market, by Application, 2020-2028 (USD Million) 1.2.4. AI-based Clinical Trials Solution Provider Market, by End-use, 2020-2028 (USD Million) 1.3. Key Trends 1.4. Estimation Methodology 1.5. Research Assumption Chapter 2. Global AI-based Clinical Trials Solution Provider Market Definition and Scope 2.1. Objective of the Study 2.2. Market Definition & Scope 2.2.1. Scope of the Study 2.2.2. Industry Evolution 2.3. Years Considered for the Study 2.4. Currency Conversion Rates Chapter 3. Global AI-based Clinical Trials Solution Provider Market Dynamics 3.1. AI-based Clinical Trials Solution Provider Market Impact Analysis (2020-2028) 3.1.1. Market Drivers 3.1.1.1. Increase in the number of clinical studies 3.1.1.2. Growing penetration of the AI-based platforms for enhancing efficiency and productivity of trials at many stages 3.1.2. Market Challenges 3.1.2.1. Lack of AI accuracy in clinical practices 3.1.2.2. Imposition of several stringent regulations on the approval of AI-based clinical trials hinders 3.1.3. Market Opportunities 3.1.3.1. Rising R&D investments in various therapeutic areas 3.1.3.2. Growing awareness and diversified applications of artificial intelligence (AI) in the field of clinical trials Chapter 4. Global AI-based Clinical Trials Solution Provider Market Industry Analysis 4.1. Porter’s 5 Force Model 4.1.1. Bargaining Power of Suppliers 4.1.2. Bargaining Power of Buyers 4.1.3. Threat of New Entrants 4.1.4. Threat of Substitutes 4.1.5. Competitive Rivalry 4.1.6. Futuristic Approach to Porter’s 5 Force Model (2018-2028) 4.2. PEST Analysis 4.2.1. Political 4.2.2. Economical 4.2.3. Social 4.2.4. Technological 4.3. Investment Adoption Model 4.4. Analyst Recommendation & Conclusion 4.5. Top investment opportunity 4.6. Top winning strategies Chapter 5. Risk Assessment: COVID-19 Impact 5.1.1. Assessment of the overall impact of COVID-19 on the industry 5.1.2. Pre COVID-19 and post COVID-19 market scenario Chapter 6. Global AI-based Clinical Trials Solution Provider Market, by Clinical Trial Phase 6.1. Market Snapshot 6.2. Global AI-based Clinical Trials Solution Provider Market by Clinical Trial Phase, Performance - Potential Analysis 6.3. Global AI-based Clinical Trials Solution Provider Market Estimates & Forecasts by Clinical Trial Phase, 2018-2028 (USD Million) 6.4. AI-based Clinical Trials Solution Provider Market, Sub Segment Analysis 6.4.1. Phase-I 6.4.2. Phase-II 6.4.3. Phase-III Chapter 7. Global AI-based Clinical Trials Solution Provider Market, by Application 7.1. Market Snapshot 7.2. Global AI-based Clinical Trials Solution Provider Market by Application, Performance - Potential Analysis 7.3. Global AI-based Clinical Trials Solution Provider Market Estimates & Forecasts by Application, 2018-2028 (USD Million) 7.4. AI-based Clinical Trials Solution Provider Market, Sub Segment Analysis 7.4.1. Oncology 7.4.2. Cardiovascular Diseases 7.4.3. Neurological Diseases or Conditions 7.4.4. Infectious Diseases 7.4.5. Others Chapter 8. Global AI-based Clinical Trials Solution Provider Market, by End-use 8.1. Market Snapshot 8.2. Global AI-based Clinical Trials Solution Provider Market by End-use, Performance - Potential Analysis 8.3. Global AI-based Clinical Trials Solution Provider Market Estimates & Forecasts by End-use, 2018-2028 (USD Million) 8.4. AI-based Clinical Trials Solution Provider Market, Sub Segment Analysis 8.4.1. Pharmaceutical Companies 8.4.2. Academia 8.4.3. Others Chapter 9. Global AI-based Clinical Trials Solution Provider Market, Regional Analysis 9.1. AI-based Clinical Trials Solution Provider Market, Regional Market Snapshot 9.2. North America AI-based Clinical Trials Solution Provider Market 9.2.1. U.S. AI-based Clinical Trials Solution Provider Market 9.2.1.1. Clinical Trial Phase breakdown estimates & forecasts, 2018-2028 9.2.1.2. Application breakdown estimates & forecasts, 2018-2028 9.2.1.3. End-use breakdown estimates & forecasts, 2018-2028 9.2.2. Canada AI-based Clinical Trials Solution Provider Market 9.3. Europe AI-based Clinical Trials Solution Provider Market Snapshot 9.3.1. U.K. AI-based Clinical Trials Solution Provider Market 9.3.2. Germany AI-based Clinical Trials Solution Provider Market 9.3.3. France AI-based Clinical Trials Solution Provider Market 9.3.4. Spain AI-based Clinical Trials Solution Provider Market 9.3.5. Italy AI-based Clinical Trials Solution Provider Market 9.3.6. Rest of Europe AI-based Clinical Trials Solution Provider Market 9.4. Asia-Pacific AI-based Clinical Trials Solution Provider Market Snapshot 9.4.1. China AI-based Clinical Trials Solution Provider Market 9.4.2. India AI-based Clinical Trials Solution Provider Market 9.4.3. Japan AI-based Clinical Trials Solution Provider Market 9.4.4. Australia AI-based Clinical Trials Solution Provider Market 9.4.5. South Korea AI-based Clinical Trials Solution Provider Market 9.4.6. Rest of Asia Pacific AI-based Clinical Trials Solution Provider Market 9.5. Latin America AI-based Clinical Trials Solution Provider Market Snapshot 9.5.1. Brazil AI-based Clinical Trials Solution Provider Market 9.5.2. Mexico AI-based Clinical Trials Solution Provider Market 9.6. Rest of The World AI-based Clinical Trials Solution Provider Market Chapter 10. Competitive Intelligence 10.1. Top Market Strategies 10.2. Company Profiles 10.2.1. Unlearn.AI, Inc. 10.2.1.1. Key Information 10.2.1.2. Overview 10.2.1.3. Financial (Subject to Data Availability) 10.2.1.4. Product Summary 10.2.1.5. Recent Developments 10.2.2. Saama Technologies 10.2.3. Antidote Technologies, Inc. 10.2.4. Innoplexus 10.2.5. Mendel.ai 10.2.6. Median Technologies 10.2.7. Symphony AI 10.2.8. BioAge Labs, Inc. 10.2.9. AiCure, LLC 10.2.10. Halo Health Systems Chapter 11. Research Process 11.1. Research Process 11.1.1. Data Mining 11.1.2. Analysis 11.1.3. Market Estimation 11.1.4. Validation 11.1.5. Publishing 11.2. Research Attributes 11.3. Research Assumption
SummaryGlobal AI-based Clinical Trials Solution Provider Market is valued at approximately USD XX million in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2028. The emergence of artificial intelligence (AI) in the research and development activities in clinical trials aids in improving operational competence, minimizing costs, and boosting drug discovery. AI technology integrated with big data helps in solving various key clinical trial challenges, which is leading the market growth. Factors such as the increase in the number of clinical studies, and growing penetration of the AI-based platforms for enhancing efficiency and productivity of trials at many stages, coupled with the development of the pharmaceutical and CROs sector are impelling the growth of the global market. For instance, as per a Statista report, in 2018, the total number of registered clinical studies worldwide was recorded at 293,259 and the figure is constantly rising and reach 409,300 studies by 2022. Accordingly, the rising clinical studies are positively influencing the growth of the AI-based Clinical Trials Solution Provider market across the globe. However, the lack of AI accuracy in clinical practices and the imposition of several stringent regulations on the approval of AI-based clinical trials hinders the growth of the market over the forecast period of 2022-2028. Also, rising R&D investments in various therapeutic areas and growing awareness and diversified applications of artificial intelligence (AI) in the field of clinical trials are anticipated to act as catalyzing factors for the market demand during the forecast period. Table of ContentsChapter 1. Executive Summary1.1. Market Snapshot 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Million) 1.2.1. AI-based Clinical Trials Solution Provider Market, by Region, 2020-2028 (USD Million) 1.2.2. AI-based Clinical Trials Solution Provider Market, by Clinical Trial Phase, 2020-2028 (USD Million) 1.2.3. AI-based Clinical Trials Solution Provider Market, by Application, 2020-2028 (USD Million) 1.2.4. AI-based Clinical Trials Solution Provider Market, by End-use, 2020-2028 (USD Million) 1.3. Key Trends 1.4. Estimation Methodology 1.5. Research Assumption Chapter 2. Global AI-based Clinical Trials Solution Provider Market Definition and Scope 2.1. Objective of the Study 2.2. Market Definition & Scope 2.2.1. Scope of the Study 2.2.2. Industry Evolution 2.3. Years Considered for the Study 2.4. Currency Conversion Rates Chapter 3. Global AI-based Clinical Trials Solution Provider Market Dynamics 3.1. AI-based Clinical Trials Solution Provider Market Impact Analysis (2020-2028) 3.1.1. Market Drivers 3.1.1.1. Increase in the number of clinical studies 3.1.1.2. Growing penetration of the AI-based platforms for enhancing efficiency and productivity of trials at many stages 3.1.2. Market Challenges 3.1.2.1. Lack of AI accuracy in clinical practices 3.1.2.2. Imposition of several stringent regulations on the approval of AI-based clinical trials hinders 3.1.3. Market Opportunities 3.1.3.1. Rising R&D investments in various therapeutic areas 3.1.3.2. Growing awareness and diversified applications of artificial intelligence (AI) in the field of clinical trials Chapter 4. Global AI-based Clinical Trials Solution Provider Market Industry Analysis 4.1. Porter’s 5 Force Model 4.1.1. Bargaining Power of Suppliers 4.1.2. Bargaining Power of Buyers 4.1.3. Threat of New Entrants 4.1.4. Threat of Substitutes 4.1.5. Competitive Rivalry 4.1.6. Futuristic Approach to Porter’s 5 Force Model (2018-2028) 4.2. PEST Analysis 4.2.1. Political 4.2.2. Economical 4.2.3. Social 4.2.4. Technological 4.3. Investment Adoption Model 4.4. Analyst Recommendation & Conclusion 4.5. Top investment opportunity 4.6. Top winning strategies Chapter 5. Risk Assessment: COVID-19 Impact 5.1.1. Assessment of the overall impact of COVID-19 on the industry 5.1.2. Pre COVID-19 and post COVID-19 market scenario Chapter 6. Global AI-based Clinical Trials Solution Provider Market, by Clinical Trial Phase 6.1. Market Snapshot 6.2. Global AI-based Clinical Trials Solution Provider Market by Clinical Trial Phase, Performance - Potential Analysis 6.3. Global AI-based Clinical Trials Solution Provider Market Estimates & Forecasts by Clinical Trial Phase, 2018-2028 (USD Million) 6.4. AI-based Clinical Trials Solution Provider Market, Sub Segment Analysis 6.4.1. Phase-I 6.4.2. Phase-II 6.4.3. Phase-III Chapter 7. Global AI-based Clinical Trials Solution Provider Market, by Application 7.1. Market Snapshot 7.2. Global AI-based Clinical Trials Solution Provider Market by Application, Performance - Potential Analysis 7.3. Global AI-based Clinical Trials Solution Provider Market Estimates & Forecasts by Application, 2018-2028 (USD Million) 7.4. AI-based Clinical Trials Solution Provider Market, Sub Segment Analysis 7.4.1. Oncology 7.4.2. Cardiovascular Diseases 7.4.3. Neurological Diseases or Conditions 7.4.4. Infectious Diseases 7.4.5. Others Chapter 8. Global AI-based Clinical Trials Solution Provider Market, by End-use 8.1. Market Snapshot 8.2. Global AI-based Clinical Trials Solution Provider Market by End-use, Performance - Potential Analysis 8.3. Global AI-based Clinical Trials Solution Provider Market Estimates & Forecasts by End-use, 2018-2028 (USD Million) 8.4. AI-based Clinical Trials Solution Provider Market, Sub Segment Analysis 8.4.1. Pharmaceutical Companies 8.4.2. Academia 8.4.3. Others Chapter 9. Global AI-based Clinical Trials Solution Provider Market, Regional Analysis 9.1. AI-based Clinical Trials Solution Provider Market, Regional Market Snapshot 9.2. North America AI-based Clinical Trials Solution Provider Market 9.2.1. U.S. AI-based Clinical Trials Solution Provider Market 9.2.1.1. Clinical Trial Phase breakdown estimates & forecasts, 2018-2028 9.2.1.2. Application breakdown estimates & forecasts, 2018-2028 9.2.1.3. End-use breakdown estimates & forecasts, 2018-2028 9.2.2. Canada AI-based Clinical Trials Solution Provider Market 9.3. Europe AI-based Clinical Trials Solution Provider Market Snapshot 9.3.1. U.K. AI-based Clinical Trials Solution Provider Market 9.3.2. Germany AI-based Clinical Trials Solution Provider Market 9.3.3. France AI-based Clinical Trials Solution Provider Market 9.3.4. Spain AI-based Clinical Trials Solution Provider Market 9.3.5. Italy AI-based Clinical Trials Solution Provider Market 9.3.6. Rest of Europe AI-based Clinical Trials Solution Provider Market 9.4. Asia-Pacific AI-based Clinical Trials Solution Provider Market Snapshot 9.4.1. China AI-based Clinical Trials Solution Provider Market 9.4.2. India AI-based Clinical Trials Solution Provider Market 9.4.3. Japan AI-based Clinical Trials Solution Provider Market 9.4.4. Australia AI-based Clinical Trials Solution Provider Market 9.4.5. South Korea AI-based Clinical Trials Solution Provider Market 9.4.6. Rest of Asia Pacific AI-based Clinical Trials Solution Provider Market 9.5. Latin America AI-based Clinical Trials Solution Provider Market Snapshot 9.5.1. Brazil AI-based Clinical Trials Solution Provider Market 9.5.2. Mexico AI-based Clinical Trials Solution Provider Market 9.6. Rest of The World AI-based Clinical Trials Solution Provider Market Chapter 10. Competitive Intelligence 10.1. Top Market Strategies 10.2. Company Profiles 10.2.1. Unlearn.AI, Inc. 10.2.1.1. Key Information 10.2.1.2. Overview 10.2.1.3. Financial (Subject to Data Availability) 10.2.1.4. Product Summary 10.2.1.5. Recent Developments 10.2.2. Saama Technologies 10.2.3. Antidote Technologies, Inc. 10.2.4. Innoplexus 10.2.5. Mendel.ai 10.2.6. Median Technologies 10.2.7. Symphony AI 10.2.8. BioAge Labs, Inc. 10.2.9. AiCure, LLC 10.2.10. Halo Health Systems Chapter 11. Research Process 11.1. Research Process 11.1.1. Data Mining 11.1.2. Analysis 11.1.3. Market Estimation 11.1.4. Validation 11.1.5. Publishing 11.2. Research Attributes 11.3. Research Assumption
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療IT)の最新刊レポート
Bizwit Research & Consulting LLP社のヘルスケアIT分野での最新刊レポート
本レポートと同じKEY WORD(clinical trial)の最新刊レポート
よくあるご質問Bizwit Research & Consulting LLP社はどのような調査会社ですか?Bizwit Research & Consulting (Bizwit Research & Consulting LLP)は世界の多様なマクロおよびマイクロ経済の動向を継続的に調査しています。 ... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/21 10:26 156.13 円 165.08 円 200.38 円 |